Emerging novel therapies in overcoming resistance to targeted therapy

Research output: Chapter in Book/Report/Conference proceedingChapterResearchpeer-review

Abstract

The recent development of small molecule inhibitors and monoclonal antibodies that target cancer-specific oncogenic driver mutations has significantly improved the outcomes of patients with various tumour types including chronic myeloid leukemia, non-small cell lung cancer and melanoma. Despite high rates of response, most patients will relapse within the first year of targeted therapy due to drug resistance. Although multiple mechanisms of resistance have been defined, these often lead to the re-activation of oncogene-regulated signaling or the activation of compensatory survival cascades. This chapter focusses on emerging therapeutic strategies to overcome and circumvent resistance to targeted therapies, with an emphasis on metastatic melanoma. A variety of therapeutic salvage approaches are being explored, including novel targeted agents, new combination therapies and consideration of drug timing and sequencing. Improved clinical trial design, treatment of earlier stage cancer patients and sensitive real-time monitoring of patient responses and resistance are critical for improving the durability of cancer targeted therapies.
LanguageEnglish
Title of host publicationCurrent applications for overcoming resistance to targeted therapies
EditorsMyron R. Szewczuk, Bessi Qorri, Manpreet Sambi
Place of PublicationSwitzerland
PublisherSpringer, Springer Nature
Chapter8
Pages223-258
Number of pages36
ISBN (Electronic)9783030214777
ISBN (Print)9783030214760
DOIs
Publication statusPublished - 2019

Publication series

NameResistance to Targeted Anti-Cancer Therapeutics
PublisherSpringer
Volume20
ISSN (Print)2196-5501
ISSN (Electronic)2196-551X

Fingerprint

Melanoma
Neoplasms
Therapeutics
Physiologic Monitoring
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Combination Drug Therapy
Oncogenes
Drug Resistance
Non-Small Cell Lung Carcinoma
Monoclonal Antibodies
Clinical Trials
Recurrence
Mutation
Survival

Keywords

  • Targeted therapies
  • Melanoma
  • Cancer therapy resistance
  • Receptor tyrosine kinases
  • Immune checkpoint blockade therapy
  • Non-small cell lung cancer

Cite this

Pinho, A. V., Lee, J. H., & Rizos, H. (2019). Emerging novel therapies in overcoming resistance to targeted therapy. In M. R. Szewczuk, B. Qorri, & M. Sambi (Eds.), Current applications for overcoming resistance to targeted therapies (pp. 223-258). (Resistance to Targeted Anti-Cancer Therapeutics; Vol. 20). Switzerland: Springer, Springer Nature. https://doi.org/10.1007/978-3-030-21477-7_8
Pinho, Andreia V. ; Lee, Jenny H. ; Rizos, H. / Emerging novel therapies in overcoming resistance to targeted therapy. Current applications for overcoming resistance to targeted therapies. editor / Myron R. Szewczuk ; Bessi Qorri ; Manpreet Sambi. Switzerland : Springer, Springer Nature, 2019. pp. 223-258 (Resistance to Targeted Anti-Cancer Therapeutics).
@inbook{06f92faa97cb47c5ad6886d6f5ffb5fd,
title = "Emerging novel therapies in overcoming resistance to targeted therapy",
abstract = "The recent development of small molecule inhibitors and monoclonal antibodies that target cancer-specific oncogenic driver mutations has significantly improved the outcomes of patients with various tumour types including chronic myeloid leukemia, non-small cell lung cancer and melanoma. Despite high rates of response, most patients will relapse within the first year of targeted therapy due to drug resistance. Although multiple mechanisms of resistance have been defined, these often lead to the re-activation of oncogene-regulated signaling or the activation of compensatory survival cascades. This chapter focusses on emerging therapeutic strategies to overcome and circumvent resistance to targeted therapies, with an emphasis on metastatic melanoma. A variety of therapeutic salvage approaches are being explored, including novel targeted agents, new combination therapies and consideration of drug timing and sequencing. Improved clinical trial design, treatment of earlier stage cancer patients and sensitive real-time monitoring of patient responses and resistance are critical for improving the durability of cancer targeted therapies.",
keywords = "Targeted therapies, Melanoma, Cancer therapy resistance, Receptor tyrosine kinases, Immune checkpoint blockade therapy, Non-small cell lung cancer",
author = "Pinho, {Andreia V.} and Lee, {Jenny H.} and H. Rizos",
year = "2019",
doi = "10.1007/978-3-030-21477-7_8",
language = "English",
isbn = "9783030214760",
series = "Resistance to Targeted Anti-Cancer Therapeutics",
publisher = "Springer, Springer Nature",
pages = "223--258",
editor = "Szewczuk, {Myron R.} and Bessi Qorri and Manpreet Sambi",
booktitle = "Current applications for overcoming resistance to targeted therapies",
address = "United States",

}

Pinho, AV, Lee, JH & Rizos, H 2019, Emerging novel therapies in overcoming resistance to targeted therapy. in MR Szewczuk, B Qorri & M Sambi (eds), Current applications for overcoming resistance to targeted therapies. Resistance to Targeted Anti-Cancer Therapeutics, vol. 20, Springer, Springer Nature, Switzerland, pp. 223-258. https://doi.org/10.1007/978-3-030-21477-7_8

Emerging novel therapies in overcoming resistance to targeted therapy. / Pinho, Andreia V.; Lee, Jenny H.; Rizos, H.

Current applications for overcoming resistance to targeted therapies. ed. / Myron R. Szewczuk; Bessi Qorri; Manpreet Sambi. Switzerland : Springer, Springer Nature, 2019. p. 223-258 (Resistance to Targeted Anti-Cancer Therapeutics; Vol. 20).

Research output: Chapter in Book/Report/Conference proceedingChapterResearchpeer-review

TY - CHAP

T1 - Emerging novel therapies in overcoming resistance to targeted therapy

AU - Pinho, Andreia V.

AU - Lee, Jenny H.

AU - Rizos, H.

PY - 2019

Y1 - 2019

N2 - The recent development of small molecule inhibitors and monoclonal antibodies that target cancer-specific oncogenic driver mutations has significantly improved the outcomes of patients with various tumour types including chronic myeloid leukemia, non-small cell lung cancer and melanoma. Despite high rates of response, most patients will relapse within the first year of targeted therapy due to drug resistance. Although multiple mechanisms of resistance have been defined, these often lead to the re-activation of oncogene-regulated signaling or the activation of compensatory survival cascades. This chapter focusses on emerging therapeutic strategies to overcome and circumvent resistance to targeted therapies, with an emphasis on metastatic melanoma. A variety of therapeutic salvage approaches are being explored, including novel targeted agents, new combination therapies and consideration of drug timing and sequencing. Improved clinical trial design, treatment of earlier stage cancer patients and sensitive real-time monitoring of patient responses and resistance are critical for improving the durability of cancer targeted therapies.

AB - The recent development of small molecule inhibitors and monoclonal antibodies that target cancer-specific oncogenic driver mutations has significantly improved the outcomes of patients with various tumour types including chronic myeloid leukemia, non-small cell lung cancer and melanoma. Despite high rates of response, most patients will relapse within the first year of targeted therapy due to drug resistance. Although multiple mechanisms of resistance have been defined, these often lead to the re-activation of oncogene-regulated signaling or the activation of compensatory survival cascades. This chapter focusses on emerging therapeutic strategies to overcome and circumvent resistance to targeted therapies, with an emphasis on metastatic melanoma. A variety of therapeutic salvage approaches are being explored, including novel targeted agents, new combination therapies and consideration of drug timing and sequencing. Improved clinical trial design, treatment of earlier stage cancer patients and sensitive real-time monitoring of patient responses and resistance are critical for improving the durability of cancer targeted therapies.

KW - Targeted therapies

KW - Melanoma

KW - Cancer therapy resistance

KW - Receptor tyrosine kinases

KW - Immune checkpoint blockade therapy

KW - Non-small cell lung cancer

U2 - 10.1007/978-3-030-21477-7_8

DO - 10.1007/978-3-030-21477-7_8

M3 - Chapter

SN - 9783030214760

T3 - Resistance to Targeted Anti-Cancer Therapeutics

SP - 223

EP - 258

BT - Current applications for overcoming resistance to targeted therapies

A2 - Szewczuk, Myron R.

A2 - Qorri, Bessi

A2 - Sambi, Manpreet

PB - Springer, Springer Nature

CY - Switzerland

ER -

Pinho AV, Lee JH, Rizos H. Emerging novel therapies in overcoming resistance to targeted therapy. In Szewczuk MR, Qorri B, Sambi M, editors, Current applications for overcoming resistance to targeted therapies. Switzerland: Springer, Springer Nature. 2019. p. 223-258. (Resistance to Targeted Anti-Cancer Therapeutics). https://doi.org/10.1007/978-3-030-21477-7_8